Autoimmune Markers in Screening for Orbital Inflammatory Disease

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2022 Apr 20

PMID 35440697

Authors

Terence Ang

Valerie Juniat

Dinesh Selva

Affiliations

Soon will be listed here.

Abstract

Purpose: Immunogenic causes of inflammation may be difficult to differentiate in the work-up of orbital inflammatory disease. The study aims to investigate the utility of autoimmune markers in the screening for orbital inflammation. Markers studied included angiotensin-converting enzyme (ACE), antinuclear antibody (ANA), anti-neutrophilic cytoplasmic autoantibodies (ANCA), extractable nuclear antigen (ENA), anti-cyclic citrullinated peptide (Anti-CCP) and anti-double stranded DNA antibody (Anti-dsDNA antibody).

Methods: A retrospective single-centre study of consecutive patients with non-infective orbital inflammation screened for autoimmune markers at presentation. Serology was interpreted alongside clinical course and other investigations (e.g. radiographic features and histopathology). Tabulated data and Pearson's Chi-square allowed analysis of trends between serology, diagnosis and the decision to biopsy.

Results: 79 patients, between 1999 and 2021, were included (50 females, mean age was 50.4 ± 17.4 years). 28 (34.6%) patients had specific orbital inflammation and 53 (65.4%) patients had non-specific orbital inflammation (NSOI). Of the 12 patients with positive serology and a specific diagnosis, only 5 (41.7%) patients had concordant serological results. There was no association between serology results and the patient undergoing biopsy (P = 0.651). Serology was unable to exclude nor differentiate NSOI from other specific conditions and ANA had limited discriminatory value between specific conditions and NSOI.

Conclusion: Serological testing alone may not provide a clear direction for further investigation of orbital inflammation and a biopsy may occur independently of the serological results. The value of autoimmune markers may lie in subsequent follow-up as patients may develop suggestive symptoms after an indeterminate positive result or initially seronegative disease.

Citing Articles

The Relevance and Potential Role of Orbital Fat in Inflammatory Orbital Diseases: Implications for Diagnosis and Treatment.

Dadson P, Ngum P, Juarez-Orozco L, Ntodie M, Loba P Ophthalmol Ther. 2024; 14(2):247-281.

PMID: 39680323 PMC: 11754589. DOI: 10.1007/s40123-024-01079-7.

Deciphering the role of HLF in idiopathic orbital inflammation: integrative analysis via bioinformatics and machine learning techniques.

Wu Z, Song Q, Liu M, Hu Y, Peng X, Zhang Z Sci Rep. 2024; 14(1):19346.

PMID: 39164324 PMC: 11336107. DOI: 10.1038/s41598-024-68890-x.

Elucidating the multifaceted roles of GPR146 in non-specific orbital inflammation: a concerted analytical approach through the prisms of bioinformatics and machine learning.

Wu Z, Li L, Xu T, Hu Y, Peng X, Zhang Z Front Med (Lausanne). 2024; 11:1309510.

PMID: 38903815 PMC: 11188444. DOI: 10.3389/fmed.2024.1309510.

The roles of IRF8 in nonspecific orbital inflammation: an integrated analysis by bioinformatics and machine learning.

Wu Z, Xu J, Hu Y, Peng X, Zhang Z, Yao X J Ophthalmic Inflamm Infect. 2024; 14(1):29.

PMID: 38900395 PMC: 11190126. DOI: 10.1186/s12348-024-00410-4.

Glutamine metabolism-related genes and immunotherapy in nonspecific orbital inflammation were validated using bioinformatics and machine learning.

Wu Z, Li N, Gao Y, Cao L, Yao X, Peng Q BMC Genomics. 2024; 25(1):71.

PMID: 38233749 PMC: 10795212. DOI: 10.1186/s12864-023-09946-6.

References

Abeles A, Abeles M . The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013; 126(4):342-8. DOI: 10.1016/j.amjmed.2012.09.014. View

Kapur R, Sepahdari A, Mafee M, Putterman A, Aakalu V, Wendel L . MR imaging of orbital inflammatory syndrome, orbital cellulitis, and orbital lymphoid lesions: the role of diffusion-weighted imaging. AJNR Am J Neuroradiol. 2008; 30(1):64-70. PMC: 3690287. DOI: 10.3174/ajnr.A1315. View

Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I . Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature. Ophthalmol Ther. 2019; 8(2):227-234. PMC: 6513923. DOI: 10.1007/s40123-019-0176-8. View

Gottenberg J, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J . Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis. 2004; 64(1):114-7. PMC: 1755190. DOI: 10.1136/ard.2003.019794. View

Lyne S, Downie-Doyle S, Lester S, Quinlivan A, Coates P, Gordon T . Primary Sjögren's syndrome in South Australia. Clin Exp Rheumatol. 2020; 38 Suppl 126(4):57-63. View

Bowman S . Primary Sjögren's syndrome. Lupus. 2018; 27(1_suppl):32-35. DOI: 10.1177/0961203318801673. View

COLLISON J, Miller N, Green W . Involvement of orbital tissues by sarcoid. Am J Ophthalmol. 1986; 102(3):302-7. DOI: 10.1016/0002-9394(86)90002-4. View

Srinivasan A, Kleinberg T, Murchison A, Bilyk J . Laboratory Investigations for Diagnosis of Autoimmune and Inflammatory Periocular Disease: Part II. Ophthalmic Plast Reconstr Surg. 2016; 33(1):1-8. DOI: 10.1097/IOP.0000000000000701. View

Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C . Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther. 2008; 10(3):R51. PMC: 2483440. DOI: 10.1186/ar2420. View

10.

Pakrou N, Selva D, Leibovitch I . Wegener's granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum. 2006; 35(5):284-92. DOI: 10.1016/j.semarthrit.2005.12.003. View

11.

Beneteau-Burnat B, Baudin B . Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Crit Rev Clin Lab Sci. 1991; 28(5-6):337-56. DOI: 10.3109/10408369109106868. View

12.

Schmidt J, Pulido J, Matteson E . Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Ophthalmol. 2011; 22(6):489-95. DOI: 10.1097/ICU.0b013e32834bdfe2. View

13.

Tan L, Davagnanam I, Isa H, Taylor S, Rose G, Verity D . Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement. Ophthalmology. 2014; 121(6):1304-9. DOI: 10.1016/j.ophtha.2013.12.003. View

14.

Gordon L . Orbital inflammatory disease: a diagnostic and therapeutic challenge. Eye (Lond). 2006; 20(10):1196-206. DOI: 10.1038/sj.eye.6702383. View

15.

Chan A, Rai A, Lake S . Orbital myositis in systemic lupus erythematosus: A case report and literature review. Eur J Rheumatol. 2020; 7(3):135-137. PMC: 7431353. DOI: 10.5152/eurjrheum.2020.19217. View

16.

Tang S, Lim R, Al-Dahmash S, Blaydon S, Cho R, Choe C . Bilateral lacrimal gland disease: clinical features of 97 cases. Ophthalmology. 2014; 121(10):2040-6. DOI: 10.1016/j.ophtha.2014.04.018. View

17.

Bijlsma W, Hene R, Mourits M, Kalmann R . Orbital mass as manifestation of Wegener's granulomatosis: an ophthalmologic diagnostic approach. Clin Exp Rheumatol. 2011; 29(1 Suppl 64):S35-9. View

18.

Locht H, Pelck R, Manthorpe R . Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sjögren's syndrome. J Rheumatol. 2008; 35(5):845-9. View

19.

Goeb V, Salle V, Duhaut P, Jouen F, Smail A, Ducroix J . Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome. Clin Exp Immunol. 2007; 148(2):281-7. PMC: 1868868. DOI: 10.1111/j.1365-2249.2007.03337.x. View

20.

Lee M, Planck S, Choi D, Harrington C, Wilson D, Dailey R . Non-specific orbital inflammation: Current understanding and unmet needs. Prog Retin Eye Res. 2020; 81:100885. DOI: 10.1016/j.preteyeres.2020.100885. View